Therapeutic hub
Neurology-Related Peptides
From CGRP-targeting migraine therapies to early work on neurodegeneration, delivery across the blood-brain barrier defines what is feasible.
Regulatory picture
Approved migraine therapeutics; most neurodegeneration work remains early.
What this area covers
Neuropeptide signalling is implicated in pain, migraine, appetite, mood, and sleep. The clearest clinical success has come from targeting calcitonin gene-related peptide signalling in migraine.
Central nervous system indications face a structural obstacle: peptides generally do not cross the blood-brain barrier efficiently, so programmes rely on peripheral targets, transport systems, or alternative delivery routes.
Fig. 02 / Molecular pathwayReading claims about cognition
Cognitive and neuroprotective claims for peptides are frequently based on animal models or small open-label studies. Treat any such claim as preliminary unless a randomised trial with prespecified cognitive endpoints exists.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.